1877 — Shanghai Junshi Biosciences Co Income Statement
0.000.00%
Last trade - 00:00
- HK$10.59bn
- HK$8.62bn
- CNY1.50bn
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
Standards: | CAS | CAS | CAS | CAS | CAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 775 | 1,595 | 4,025 | 1,453 | 1,503 |
Cost of Revenue | |||||
Gross Profit | 684 | 1,218 | 2,767 | 927 | 868 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 1,515 | 3,251 | 4,583 | 4,119 | 3,960 |
Operating Profit | -740 | -1,656 | -558 | -2,666 | -2,457 |
Gain / Loss on Sale of Assets | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -767 | -1,672 | -595 | -2,677 | -2,492 |
Provision for Income Taxes | |||||
Net Income After Taxes | -748 | -1,669 | -731 | -2,584 | -2,536 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -747 | -1,669 | -721 | -2,388 | -2,283 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -747 | -1,669 | -721 | -2,388 | -2,283 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.959 | -2.03 | -0.811 | -2.64 | -2.43 |
Dividends per Share |